168: Analyzing Phase 2 Data for PACAP Targeting Therapy Bocunebart in Migraine

About this episode

Jessica Ailani discusses emerging phase 2 data on bocunebart, a PACAP-targeting monoclonal antibody for migraine prevention.

Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this Mind Moments episode, Jessica Ailani, MD, director of the MedStar Georgetown Headache Center, discusses emerging phase 2 data on bocunebart (Lundbeck), a PACAP-targeting monoclonal antibody being developed for migraine prevention. Presented at the 2026 American Headache Society Annual Meeting, findings from the PROCEED trial demonstrated efficacy in patients with episodic or chronic migraine who had previously failed 1 to 4 preventive therapies, including those considered treatment refractory. The conversation explores the efficacy and safety findings from PROCEED, pooled analyses from chronic migraine populations, and a separate study evaluating coadministration of bocunebart with ubrogepant. Ailani also discusses the potential role of PACAP-targeting therapies within the evolving migraine treatment landscape, considerations for future combination strategies, and key questions investigators will need to address as the program moves toward phase 3 development. Looking for more Headache & migraine discussion? Check out the…

People in this episode

Guests: Jessica Ailani, MD, Jessica Ailani

Topics covered

• migraine prevention
• PACAP-targeting therapy
• clinical trial data
• safety and efficacy
• combination strategies

Keywords

• bocunebart
• migraine
• PACAP
• clinical trial
• safety
• efficacy
• combination therapy

Mentioned in this episode

Organizations: MedStar Georgetown Headache Center, Lundbeck, NeurologyLive

Products: bocunebart, ubrogepant

More episodes of NeurologyLive® Mind Moments®

• 167: New AASM Guidance on Combination Treatment for Chronic Insomnia · May 29, 2026 · 20 min
• 166: Understanding RNFL Asymmetry as a Biomarker in Pediatric MS · May 15, 2026 · 15 min
• 165: Addressing Cognitive Decline in Parkinson Disease · May 1, 2026 · 20 min
• 164: Tremor vs Dyskinesia: Practical Bedside Clues for Clinicians · April 17, 2026 · 25 min
• 163: The Clinical Reality of Seronegative Myasthenia Gravis · April 3, 2026 · 17 min
• Key Challenges Facing Neurology in the Year Ahead · March 13, 2026 · 19 min